Rosuvastatin 20 mg tablet
Description
ROSUROOT-20
Rosuvastatin 20 mg Tablets
Division: DIABGLYM
Composition
Each film-coated tablet contains:
Rosuvastatin Calcium IP equivalent to Rosuvastatin — 20 mg
Excipients — q.s.
Colour: Approved colour used
Dosage form: Film-coated oral tablet
Product Description
ROSUROOT-20 contains Rosuvastatin 20 mg, a high-intensity statin therapy formulated for the effective management of hypercholesterolemia, mixed dyslipidemia, diabetic dyslipidemia, and the prevention of atherosclerotic cardiovascular disease. Rosuvastatin is a potent HMG-CoA reductase inhibitor that significantly lowers LDL cholesterol, total cholesterol, non-HDL cholesterol, apolipoprotein B, and triglycerides while improving HDL cholesterol levels.
Rosuvastatin 20 mg is considered a high-intensity lipid-lowering therapy and is widely recommended for patients at high cardiovascular risk, including those with coronary artery disease, diabetes mellitus, hypertension, metabolic syndrome, chronic kidney disease, and a history of myocardial infarction or stroke. It helps reduce the progression of atherosclerosis, stabilize vulnerable plaques, improve endothelial function, and significantly lower the risk of major cardiovascular events.
ROSUROOT-20 is particularly beneficial for patients requiring aggressive LDL cholesterol reduction and long-term cardiovascular protection, making it an important therapy in preventive cardiology and diabetic cardiovascular care.
Technical Knowledge of Rosuvastatin
Rosuvastatin selectively inhibits HMG-CoA reductase, the rate-limiting enzyme responsible for cholesterol biosynthesis in the liver. This inhibition decreases hepatic cholesterol production and increases LDL receptor expression on hepatocytes, resulting in enhanced clearance of circulating LDL cholesterol from the bloodstream.
Rosuvastatin also reduces hepatic VLDL synthesis, decreases triglyceride-rich lipoproteins, improves endothelial nitric oxide activity, reduces vascular inflammation, and stabilizes atherosclerotic plaques. Its long half-life and potent LDL-lowering efficacy make it one of the most effective statins available for cardiovascular risk reduction.
Mechanism of Action
Rosuvastatin inhibits HMG-CoA reductase, reduces hepatic cholesterol synthesis, increases LDL receptor activity, lowers LDL cholesterol and total cholesterol, reduces VLDL production, improves endothelial function, decreases vascular inflammation, and stabilizes atherosclerotic plaques.
Key Benefits
High-intensity LDL cholesterol reduction
Significant reduction in total cholesterol and non-HDL cholesterol
Reduces triglyceride levels
Improves HDL cholesterol
Slows progression of atherosclerosis
Stabilizes atherosclerotic plaques
Reduces the risk of myocardial infarction and stroke
Provides long-term cardiovascular protection
Suitable for intensive lipid management under medical supervision
Clinical Applications
ROSUROOT-20 is commonly prescribed for primary hypercholesterolemia, mixed dyslipidemia, diabetic dyslipidemia, familial hypercholesterolemia, coronary artery disease, secondary prevention after myocardial infarction, ischemic stroke prevention, peripheral arterial disease, and cardiovascular risk reduction in high-risk patients.
Facts About Rosuvastatin
Rosuvastatin is one of the most potent statins available for lowering LDL cholesterol and has extensive clinical evidence supporting cardiovascular risk reduction. High-intensity Rosuvastatin therapy can produce substantial LDL reduction and significantly decrease major adverse cardiovascular events. It is recommended in multiple international cardiology and diabetes guidelines for high-risk patients requiring aggressive lipid lowering.
Key Facts
High-intensity statin therapy
Rosuvastatin 20 mg for aggressive LDL reduction
Provides cardiovascular and cerebrovascular protection
Supports long-term lipid management
Evidence-based therapy for atherosclerotic cardiovascular disease
Quality-assured pharmaceutical formulation
PCD Pharma Franchise Opportunity
ROSUROOT-20 is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The rapidly increasing prevalence of dyslipidemia, diabetes, hypertension, obesity, and cardiovascular disease creates strong prescription demand and long-term market potential for this formulation.
Why Choose ROSUROOT-20 for PCD Pharma Franchise?
High prescription potential
Strong physician and cardiologist acceptance
Attractive monopoly franchise opportunity
Competitive pricing
Promotional support available
Visual aids and marketing inputs
Consistent product quality
Excellent repeat business potential
Third Party Manufacturing
Chemsroot Pharmaceutical offers Third Party Manufacturing of Rosuvastatin 20 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses.
Our Third Party Manufacturing Services Include
Private label manufacturing
Contract manufacturing
Custom brand manufacturing
Loan license manufacturing
DCGI-compliant production
GMP-certified manufacturing
Batch manufacturing documentation
Product registration support
Customized packaging and artwork
Monopoly franchise packaging
Bulk manufacturing capability
Manufacturing Features
Pharmaceutical-grade raw materials
IP/BP/USP quality standards
In-process quality control
Finished product testing
Stability-oriented formulation
Moisture-controlled tablet manufacturing
Blister and Alu-Alu packaging options
ROSUROOT-20 from DIABGLYM combines intensive lipid lowering, comprehensive cardiovascular protection, evidence-based statin therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable and high-intensity Rosuvastatin formulation.
